Literature DB >> 7651894

Adrenomedullin and calcitonin gene-related peptide interact with the same receptor in cultured human neuroblastoma SK-N-MC cells.

U Zimmermann1, J A Fischer, R Muff.   

Abstract

Inhibition of human [125I]calcitonin gene-related peptide-I ([125I]hCGRP-I) binding by human adrenomedullin (hADM), its N-terminal truncated fragments, CGRP and amylin, and cyclic AMP accumulation were examined in the human neuroblastoma cell line SK-N-MC. Binding of [125I]hCGRP-I (125 pM) was inhibited by hCGRP-I, hADM(1-52), hADM(13-52), and human amylin with IC50 of 0.32 +/- 0.06, 2.11 +/- 0.26, 3.45 +/- 0.54, and 68.8 +/- 6.6 nM, respectively. hCGRP-I(8-37) and hADM(22-52), which lack the N-terminal ring structure, inhibited [125I]hCGRP-I binding with IC50 of 2.35 +/- 0.45 and > 1000 nM. hCGRP-I, hADM(1-52), hADM(13-52) and human amylin stimulated cAMP accumulation with EC50 of 0.40 +/- 0.05, 18.1 +/- 2.6, 51.3 +/- 9.0 and 925 +/- 159 nM, respectively. hCGRP-I(8-37) (100 nM) antagonized hCGRP-I and hADM(1-52) stimulated cAMP production with the same Ki of 16.6 +/- 1.2 and 16.8 +/- 1.1 nM. In conclusion, human ADM, which is more distantly related to CGRP than amylin, interacts more potently with the CGRP receptor in SK-N-MC cells than amylin. The N-terminal ring structure of hADM, unlike that of hCGRP, is essential for binding to the CGRP receptor. Coupling of hADM binding to cAMP stimulation is less efficient than for hCGRP-I and is reduced by deletion of the unique 12 amino acid sequence of hADM N-terminal to the ring structure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651894     DOI: 10.1016/0196-9781(94)00195-c

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  7 in total

Review 1.  The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors.

Authors:  Debbie L Hay; Alex C Conner; Stephen G Howitt; David M Smith; David R Poyner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Rat-2 fibroblasts express specific adrenomedullin receptors, but not calcitonin-gene-related-peptide receptors, which mediate increased intracellular cAMP and inhibit mitogen-activated protein kinase activity.

Authors:  H A Coppock; A A Owji; C Austin; P D Upton; M L Jackson; J V Gardiner; M A Ghatei; S R Bloom; D M Smith
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

3.  A rat skeletal muscle cell line (L6) expresses specific adrenomedullin binding sites but activates adenylate cyclase via calcitonin gene-related peptide receptors.

Authors:  H A Coppock; A A Owji; S R Bloom; D M Smith
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

4.  Characterization and effects on cAMP accumulation of adrenomedullin and calcitonin gene-related peptide (CGRP) receptors in dissociated rat spinal cord cell culture.

Authors:  Mohammad A Takhshid; David R Poyner; Jean-Guy Chabot; Alain Fournier; Weiya Ma; Wen-Hua Zheng; Ali A Owji; Remi Quirion
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

5.  A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation.

Authors:  K Hoehlig; K W Johnson; E Pryazhnikov; C Maasch; A Clemens-Smith; W G Purschke; S Vauléon; K Buchner; F Jarosch; L Khiroug; A Vater; S Klussmann
Journal:  Br J Pharmacol       Date:  2015-03-27       Impact factor: 8.739

6.  Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvascular permeability.

Authors:  Uwe Pfeil; Muhammad Aslam; Renate Paddenberg; Karin Quanz; Chia L Chang; Jae-Il Park; Barbara Gries; Amir Rafiq; Petra Faulhammer; Anna Goldenberg; Tamara Papadakis; Thomas Noll; Sheau Y T Hsu; Norbert Weissmann; Wolfgang Kummer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-14       Impact factor: 5.464

7.  CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.

Authors:  J Zeller; K T Poulsen; J E Sutton; Y N Abdiche; S Collier; R Chopra; C A Garcia; J Pons; A Rosenthal; D L Shelton
Journal:  Br J Pharmacol       Date:  2008-09-08       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.